The peer-reviewed validation of QSM MRI as a biomarker de-risks the Phase 3 program for ATH434 in MSA. Monitor for the End-of-Phase 2 meeting outcome in mid-2026, which could trigger a catalyst for the stock.
Price Chart
Executive Summary
Alterity Therapeutics announced a peer-reviewed publication in NeuroImage demonstrating that QSM MRI can detect disease-specific iron accumulation in MSA patients, distinguish MSA from Parkinson's disease, and correlate with clinical severity. The company remains on track for an End-of-Phase 2 meeting with the FDA in mid-2026 to initiate a Phase 3 trial of ATH434.
Key Facts
- Peer-reviewed study in NeuroImage validates QSM MRI as a biomarker for iron dysregulation in MSA.
- QSM MRI distinguished MSA from Parkinson's disease with moderate-to-good accuracy (AUC = 0.76–0.79).
- Higher iron content correlated with greater disease severity on UMSARS.
- Alterity is on track for End-of-Phase 2 meeting with FDA in mid-2026.
- ATH434 has Fast Track and Orphan Drug Designations from FDA and European Commission.
- Phase 2 trial showed robust clinical efficacy, target engagement, and favorable safety profile.
Financial Impact
No financial figures disclosed; publication supports biomarker validation for ATH434 Phase 3 program.
Risk Factors
- Phase 3 trial may fail to replicate Phase 2 efficacy results.
- Regulatory feedback from End-of-Phase 2 meeting could delay or require additional studies.
- Small market cap ($72M) and OTC listing increase volatility and liquidity risk.
- No revenue or near-term commercialization timeline.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3291770 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.08 (+0.48%) |
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.08 (−0.48%) |
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.08 (−0.48%) |
Oct 21, 2026 6d ago | 6-K | $2.39 | awaiting T+60 | — | $2.08 (−12.97%) |
Oct 21, 2026 6d ago | 6-K | $2.39 | awaiting T+60 | — | $2.08 (−12.97%) |
Oct 19, 2026 8d ago | 6-K | $2.43 | awaiting T+60 | — | $2.08 (−14.40%) |
Oct 9, 2026 18d ago | 6-K | $3.12 | awaiting T+60 | — | $2.08 (−33.33%) |
Oct 5, 2026 21d ago | Press Release | $3.22 | awaiting T+60 | — | $2.08 (−35.40%) |
Oct 5, 2026 22d ago | 6-K | $3.22 | awaiting T+60 | — | $2.08 (−35.40%) |
Sep 25, 2026 4w ago | 6-K | $3.67 | awaiting T+60 | — | $2.08 (−43.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers